Samuel Koszer, MD
Neurology · Poughkeepsie, NYNPI 1982697975
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (42.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by EMD Serono, Inc. at 59.7% of the total. Reporting peaked in 2019 at $9,436 and has fallen 79.8% since, to $1,907 in 2025.
Across 345 payments — averaging $47.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$10K
- Neurocrine Biosciences, Inc.$1K
- AbbVie$1K
- UCB, Inc.$506
- Teva Pharmaceuticals USA, Inc.$423
- Jazz Pharmaceuticals Inc.$405
- plus $3K from 36 others
Across 2 payments — averaging $2555.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$5K
What the payments were for
- Speaking & faculty fees$6,37039%
- Travel & lodging$2,41115%
- Food & beverage$6,91642%
- Education$7675%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mavenclad$8,920
How this compares
$16,464 in reported general payments places this provider in the 80th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SolirisEculizumab | 13 | $667,564 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $437,357 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 11 | $362,855 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 17 | $259,561 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 14 | $201,935 |
| Rebif RebidoseInterferon Beta-1a/Albumin | 12 | $162,970 |
| Nurtec OdtRimegepant Sulfate | 87 | $145,571 |
| EpidiolexCannabidiol (Cbd) | 33 | $136,951 |
| AustedoDeutetrabenazine | 21 | $127,920 |
| XywavSodium,calcium,mag,pot Oxybate | 12 | $121,362 |
| Emgality PenGalcanezumab-Gnlm | 139 | $112,617 |
| TecfideraDimethyl Fumarate | 12 | $108,838 |
| Aimovig AutoinjectorErenumab-Aooe | 114 | $95,774 |
| XcopriCenobamate | 66 | $94,688 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 11 | $85,266 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaSoliris | $138 | $667,56413 claims |
| PfizerPanzyga, Nurtec Odt | $211 | $508,42798 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $79 | $437,35713 claims |
| UCB, Inc.Briviact, Neupro | $506 | $142,93989 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $423 | $127,92021 claims |
| BiogenTecfidera | $90 | $108,83812 claims |
| AbbVieUbrelvy, Qulipta | $1,093 | $66,97637 claims |
| Lundbeck LLCOnfi | $62 | $60,23523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,623 neurology providers in New York.
Other neurology in Poughkeepsie
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- Nicolas SaikaliAmherst$1.5M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
- Robert FeketeHawthorne$1M
- Jennifer McVigeAmherst$982K
- Warren SpinnerPort Jefferson Station$791K
- Richard LiptonBronx$753K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.